Monoclonal antibody therapy in sinonasal disease.

Related Articles

Monoclonal antibody therapy in sinonasal disease.

Am J Rhinol Allergy. 2017 Mar 09;:

Authors: E Chiarella S, Sy H, T Peters A

Abstract
Chronic rhinosinusitis (CRS) affects 12.5% of the U.S.
POPULATION: CRS can be divided into CRS with nasal polyps (CRSwNP) and CRS without nasal polyps. Some individuals with CRSwNP do not respond to standard-of-care medical and surgical management. For these individuals, targeted biologic agentsare emerging as an important therapeutic alternative. In this review, we described the most-relevant studies that addressed the use of anti-immunoglobulin E (omalizumab), anti-interleukin 5 (mepolizumab and reslizumab), and anti-interleukin 4/interleukin 13 (dupilumab) monoclonal antibodies for the treatment of CRSwNP. In addition, we discussed the importance of some of these clinical trials in identifying new CRS endotypes based on distinct inflammatory profiles.

PMID: 28281440 [PubMed - as supplied by publisher]

http://ift.tt/2mvq86Q